Pfizer Asks Court To Keep Purepac’s Neurontin Generic Off The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Brand company’s arguments in support of a preliminary injunction could be bolstered by the fact that, unlike Ivax’ product, Purepac’s gabapentin generic is AB-rated and the Alpharma division has said a launch would not hinge on resolution of patent litigation with Pfizer.
You may also be interested in...
Ivax To Launch Neurontin Generics Early Under Settlement With Alpharma
The company's AB-rated generics of Neurontin capsules can come to market two weeks before Alpharma's 180-day exclusivity period runs out; Ivax' gabapentin tablets will be able to enter the market six weeks early. The settlement ends Ivax' challenge of FDA's patent-based award of generic exclusivity for Pfizer's epilepsy agent.
Ivax To Launch Neurontin Generics Early Under Settlement With Alpharma
The company's AB-rated generics of Neurontin capsules can come to market two weeks before Alpharma's 180-day exclusivity period runs out; Ivax' gabapentin tablets will be able to enter the market six weeks early. The settlement ends Ivax' challenge of FDA's patent-based award of generic exclusivity for Pfizer's epilepsy agent.
Gabapentin Injunction Hearing Continued
A Newark, N.J. federal judge will continue to hear arguments Sept. 27 on Pfizer's request for a preliminary injunction against the launch of Purepac's generic version of Neurontin